Key Highlights
- ICMR initiates commercialization of recombinant multi‑stage malaria vaccine AdFalciVax.
- Expression of Interest open to pharma manufacturers for technology transfer.
- Project targets Plasmodium falciparum and aims at reducing community transmission.
- Development planned over 7 years with four distinct phases.
- Goal: reduce dependence on foreign supplies and accelerate vaccine rollout.
Detailed Insights
Vaccine profile: AdFalciVax is engineered by the ICMR Regional Medical Research Centre in Bhubaneswar. It incorporates antigens from multiple developmental stages of P. falciparum, intending to stimulate robust cellular and humoral responses. The recombinant design allows scalable production using existing manufacturing platforms.
Commercialization strategy: By releasing an Expression of Interest (EoI), ICMR invites qualified companies to acquire the technology. Selected partners will benefit from comprehensive technical support and quality‑control guidance throughout all phases, ensuring safety and efficacy standards are met prior to market release.
Timeline and milestones: The 7‑year schedule is split into four developmental stages, each accompanied by a six‑month flexibility buffer to absorb context‑specific delays. Key milestones include proof‑of‑concept trials, phase‑I/II studies, regulatory submission, and large‑scale manufacturing scale‑up.
Public health impact: India bears a high malaria burden, with P. falciparum responsible for the majority of severe cases in remote tribal districts. A domestically produced vaccine can elevate affordability, broaden coverage, and support the national objective of malaria elimination by 2030.
Key Concepts
- Recombinant vaccine: A biological preparation produced by genetically engineered microorganisms that expresses parasite antigens.
- Multi‑stage targeting: Inclusion of antigens reflecting different life‑cycle stages to interrupt transmission at several points.
- Technology transfer: Transfer of know‑how and processes from research institution to industry for commercial production.
- Expression of Interest (EoI): A formal invitation for potential partners to submit proposals for collaboration.
- Plasmodium falciparum: The species of malaria parasite that causes the most severe human infections.